Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bharat Biotech's...

    Bharat Biotech's chikungunya vaccine enters clinical trials

    Written by Ruby Khatun Khatun Published On 2017-06-06T12:12:44+05:30  |  Updated On 6 Jun 2017 12:12 PM IST
    Bharat Biotechs chikungunya vaccine enters clinical trials

    Hyderabad: Bharat Biotech said that the phase 1 human clinical trials of the indigenously developed chikungunya (CHIKV) vaccine is underway in India to evaluate its safety, tolerability and immunogenicity.


    According to a press release issued by the vaccine maker, the "placebo-controlled" study involving 60 healthy volunteers would test escalating doses of the vaccine in prime-boost regimen.


    The company developed CHIKV vaccine using an isolate of the virus from Indian epidemic and the candidate vaccine was approved by the Drug Controller General of India for phase 1 clinical trials in 2016, it said.


    Bharat Biotech Chairman and Managing Director Krishna Ella said chikungunya is one of the most dreaded viruses in modern times, and developing an efficient vaccine to prevent it means a lot, for people at risk of the infection.


    "Our pre-clinical studies were promising and we hope that the first in human clinical trials successfully meet with the clinical end points," Ella said.


    Bharat Biotech filed a globally pioneering patent in 2007 for CHIKV drawing priority from 2006, and followed up with a second patent in 2011. Patents have been granted in USA, Europe, China, Indonesia and South Africa, the release said.


    If phase 1 clinical testing is successful, Bharat Biotech plans to advance the vaccine into phase II and III clinical development.


    According to WHO, chikungunya has been identified in over 60 countries. It is a viral disease (genus Alphavirus) which is transmitted to humans by infected mosquitoes.

    Bharat Biotechchikungunyachikungunya vaccineclinical trialsDrug Controller General of IndiaKrishna Ellaphase 1 human clinical trialsWHO
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok